AstraZeneca has welcomed the announcement from the US government for the purchase of an additional 500,000 doses of Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the pre-exposure prophylaxis (prevention) of COVID-19. Delivery of the additional 500,000 doses is anticipated in the first quarter of 2022.
This follows the previous government agreement for the purchase of 700,000 doses of Evusheld, AstraZeneca notified in a statement.
Iskra Reic, Executive Vice President, Vaccines and Immune Therapies, AstraZeneca, said, “…….. Evusheld is the only antibody therapy to receive Emergency Use Authorisation (EUA) in the US for pre-exposure prophylaxis and one of only two authorised antibody therapies to show neutralising activity against Omicron and all other variants.”
Additional details on the agreement will be forthcoming in coming weeks, the statement further said.